MarketInOut Stock Screener Log In | Sign Up
 

Belite Bio Inc ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026 11:37
Belite Bio Inc ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,051.7 mln
Float21.00 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

228.89
Exceptional upside

Relative Strength

40 / 100
Slightly lagging

ROE

-18.50
Negative

ROA

-18.14
Deeply negative

Business Description

Belite Bio is a San Diego-based drug development company focused on creating treatments for serious eye conditions that currently have few or no effective options. Its most advanced drug, Tinlarebant, is taken by mouth and is currently in Phase 3 trials for patients with Stargardt disease and geographic atrophy, two conditions that cause progressive vision loss. The company is also working on a separate oral drug targeting liver disease, type 2 diabetes, and gout. Founded in 2016, Belite Bio operates as part of Lin Bioscience International Ltd.

Key Fundamentals

EPS-2.74
ROE-18.50
ROIC-28.89
ROA-18.14
EBITDA, mln-112
EV / EBITDA-61.08
EV / EBIT-61.02

Quote Details

Last 147.58
Change -2.69 (-1.79%)
Open 150.70
Volume 19,564
Turnover 2,887,255
Average Volume 150,427

Financial Ratios

Leverage Ratio1.02
Current Ratio33.56
Price / Book8.80
Price / Tangible Book8.80

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price228.89
Short Ratio5.12
Short % of Float5.04

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.36% 83 / 100   
1 Month -12.9% 28 / 100   
2 Months -3.44% 46 / 100   
6 Months -8.48% 39 / 100   
1 Year 65.15% 94 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog